Get the Stockscreener App
48.61
2.49%
-1.24
Pre-market:
48.88
0.27
+0.56%
Scholar Rock Holding Corp stock is traded at $48.61, with a volume of 2.05M.
It is down -2.49% in the last 24 hours and down -16.48% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$49.85
Open:
$50.08
24h Volume:
2.05M
Relative Volume:
1.30
Market Cap:
$5.92B
Revenue:
$47.30M
Net Income/Loss:
$-408.73M
P/E Ratio:
-13.55
EPS:
-3.5865
Net Cash Flow:
$-303.86M
1W Performance:
-0.84%
1M Performance:
-16.48%
6M Performance:
+14.92%
1Y Performance:
+44.22%
1-Day Range:
$48.21
$50.41
1-Week Range:
$45.88
$51.73
52-Week Range:
$27.07
$61.76
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
48.61 | 5.92B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK Maintains Buy Rating by Truist Securities -- Price Target R - gurufocus.com
Truist raises Scholar Rock stock price target on drug pricing update By Investing.com - Investing.com Canada
No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust. - Stock Titan
Scholar Rock’s Isembyld approval sets up rapid sales ramp - S&P Global
Scholar Rock Holding Corporation (SRRK) stock price, news, quote and history - Yahoo Finance UK
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade - MarketBeat
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SRRK Maintains Overweight Rating by JP Morgan -- Price Target Ra - gurufocus.com
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
JPMorgan raises Scholar Rock stock price target to $70 on launch outlook - Investing.com
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding (SRRK) Won FDA Approval, Is The Stock Still Trading At A Discount? - simplywall.st
Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group - MarketBeat
HC Wainwright Lowers Earnings Estimates for Scholar Rock - MarketBeat
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale? - finance.yahoo.com
Scholar Rock (NASDAQ: SRRK) Updates FDA Safety Requirements for ISEMBYLD Post-Approval - Kalkine Media
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions - Yahoo Finance
Piper Sandler raises Scholar Rock stock price target on pricing By Investing.com - Investing.com South Africa
Scholar Rock (SRRK) Gains FDA Approval for Isembyld Amid Post-Ma - GuruFocus
Scholar Rock Shares Fall After Barclays Downgrade - marketscreener.com
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says - marketscreener.com
Scholar Rock (SRRK) Shares Drop Amid Barclays Downgrade Despite FDA Approval - GuruFocus
Scholar Rock clarifies post-marketing requirements for ISEMBYLD after FDA approval - Investing.com
Scholar Rock (NASDAQ:SRRK) Shares Down 7.1%Here's What Happened - MarketBeat
Form 8K Scholar Rock Holding Corp For: 15 September By Investing.com - Investing.com Australia
SRRK Maintained by Wedbush -- Price Target Raised to $70 - gurufocus.com
UBS reiterates Buy on Scholar Rock stock, keeps $60 price target - Investing.com
Scholar Rock Updates FDA Post-Marketing Safety Requirements for ISEMBYLD Following Investor Call Correction - kalkinemedia.com
H.C. Wainwright raises Scholar Rock stock price target on FDA approval - Investing.com UK
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $70 - gurufocus.com
Barclays downgrades Scholar Rock stock rating on valuation By Investing.com - Investing.com Australia
Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55 - marketscreener.com
Barclays Downgrades Scholar Rock (SRRK) to Equal Weight Despite Isembyld Approval - gurufocus.com
SRRK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Form 8K Scholar Rock Holding Corp For: 14 September By Investing.com - Investing.com Australia
Scholar Rock shares: TD Cowen keeps buy on FDA approval, broad label - Investing.com UK
SRRK Maintained by Citigroup -- Price Target Raised to $74 - GuruFocus
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy - Benzinga
Scholar Rock Holding Corporation FDA Approval Call Transcript - GuruFocus
Why is Scholar Rock stock surging 9% today? By Investing.com - Investing.com Australia
Raymond James raises Scholar Rock stock price target on FDA approval - Investing.com Australia
Truist raises Scholar Rock stock price target on SMA drug approval - Investing.com India
Why is Scholar Rock stock surging 9% today? - Investing.com
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
SRRK Shares Surge 12% After FDA Approval of Isembyld for Spinal Muscular Atrophy - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):